31 mei 2019: 

Komende week is er weer ASCO 2019. Hier een aantal aanbevolen abstracten over hersentumoren en het centrale zenuwstelsel door artsen die zelf voor ASCO werken. Klik op de nummers voor de abstracten.

Published in Oncology and

Expert Opinion / Conference Coverage · May 29, 2019

ASCO 2019: Abstract Recommendations From Dr. Roger Stupp for CNS Malignancies

Central Nervous System Tumors

Session: Central Nervous System Tumors
Sunday June 2, 2019; 8:00 AM–11:00 AM

2011 A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM). M Khasraw, KL McDonald, M Rosenthal

2013 Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. W Wick, T Kessler, M Platten, et al

2016 SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. MS Ahluwalia, DA Reardon, AP Abad, et al

2026 Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. C Cordova, MM Syeda, B Corless, et al

2028 Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements. E Franceschi, D De Biase, A Pession, et al

2037 Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results. G Lamberti, E Franceschi, A Tosoni, et al

2050 Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma. M Shirahata, J Adachi, K Kobayashi, et al

2061 Are patients with oligodendroglioma at higher risk for radiation neurotoxicity? H Ahmad, SH Patel, J Donahue, et al

2066 Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. BY Lu, R Gupta, T Stewart, et al

Session: Central Nervous System Tumors
Monday June 3, 2019; 1:15 PM–4:15 PM

2000 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. MJ Van Den Bent, S Erridge, MA Vogelbaum, et al

2001 Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial. C Balana, CM Barroso, S Del Barco Berron, et al

2002 Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. EH Bell, M Won, JL Fleming, et al

2004 Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas. A Natsume, T Wakabayashi, Y Miyakita, et al

Brain Metastases

Session: Central Nervous System Tumors
Monday June 3, 2019; 1:15 PM–4:15 PM

2006 Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. AE Drilon, SG DuBois, AF Farago, et al

Plaats een reactie ...

Reageer op "ASCO 2019: Aanbevolen abstracten over hersentumoren en centrale zenuwstelsel van ASCO 2019"

Gerelateerde artikelen

Gerelateerde artikelen

ASCO 2021: aanbevolen abstracten >> ASCO 2019: Aanbevolen abstracten >> ASCO 2018: Belangrijke abstracten >> ASCO 2022: aanbevolen abstracten >>